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Despite their high bacterial load, bacteraemia is rare in patients with cystic fibrosis (CF). We report an adult with CF who developed
Pseudomonas aeruginosa bacteraemia during an episode of acute appendicitis. The Pseudomonas aeruginosa isolated from the blood culture was
confirmed by molecular typing to be the same transmissible strain responsible for the patient's chronic pulmonary infection. We hypothesise that
this patient's bacteraemia was caused by Pseudomonas aerunginosa in swallowed sputum, crossing the inflamed appendiceal wall and entering
the blood stream.
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Bacteraemia in patients with cystic fibrosis (CF) is rare, even
in those who are febrile during infective exacerbations [1,2].
This is thought to be due to potent humoral and cellular defence
mechanisms in response to chronic pulmonary infection. We
present a case of Pseudomonas aeruginosa bacteraemia in a
patient with CF and acute appendicitis. We hypothesise that the
source bacteraemia was P. aerunginosa in swallowed sputum
that crossed the inflamed but intact, appendiceal wall and
entered the blood stream.2. Case history
A 25 year old female with CF presented to the Emergency
Department with a 12 hour history of abdominal pain, pyrexia⁎ Corresponding author at: Manchester Adult Cystic Fibrosis Centre,
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doi:10.1016/j.jcf.2011.06.009and elevated blood glucose measurements. She had been
diagnosed with CF (ΔF508 homozygous) as an infant due to
failure to thrive and had exocrine pancreatic insufficiency. She
received insulin for CF related diabetes mellitus and was
chronically infected with a transmissible strain of P. aeruginosa
(Manchester strain) [3]. At the time of presentation her lung
function was: FEV1 1.3 L (41% predicted) and FVC 1.75 L
(46% predicted). Despite extensive physiotherapy input, she
had always been reluctant to expectorate her sputum and
would usually swallow it. There had been no significant
gastrointestinal problems and her BMI was 21. She did not have
a totally implanted venous access device (TIVAD).
The patient's pain was initially generalised across her
abdomen and then became localised to the right iliac fossa
(RIF). On examination she was pyrexial (38.5 °C) and looked
unwell. Palpation of her abdomen revealed guarding and
tenderness in the RIF. Urinalysis was unremarkable and a
pregnancy test was negative. An abdominal radiograph
showed faecal loading but no dilated loops of bowel. Initial
blood tests were normal apart from an elevated white cell count
(11.7×109/L), platelet count (528×109/L), CRP (34 mg/L) andd by Elsevier B.V. All rights reserved.
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inal ultrasound scan was undertaken but this was inconclusive as
the appendix could not be visualised.
After discussions between the surgical and medical team the
patient was admitted to the ward for observation. During this
period the patient remained pyrexial, 2 further sets of blood
cultures were therefore taken and the intravenous (IV)
cefuroxime that had been prescribed was changed to IV
tobramycin and imipenem. After a 24 hour observation, the
patient was not showing any signs of improvement and the
surgeons decided to take her to theatre. The appendix was
found to be thickened and inflamed but not perforated.
An appendicectomy was performed which went without
complication. Subsequent histology confirmed appendicitis.
Post-operatively, the patient made a good recovery although
she had a persistent, low-grade pyrexia. After 48 hours Gram-
negative rods were identified from the first set of blood cultures.
All three blood cultures isolated P. aeruginosa after 1 to 3 days
of incubation. Although this organism was multi-resistant, it
was sensitive to tobramycin and imipenem. The patient
completed 10 days of IV antibiotics and made a full recovery.
Repeat blood cultures taken 5 days post-operatively were
negative after 5 days of incubation. Subsequently the
P. aeruginosa isolates were sent for molecular typing (pulsed-
field gel electrophoresis), this confirmed that they were the
same transmissible strain (Manchester strain) responsible for the
patients chronic pulmonary infection.
3. Discussion
Despite their high bacterial load, a prospective study only
found the incidence of bacteraemia in febrile patients with
cystic fibrosis to be 1.2% [1]. This may relate to potent humoral
and cellular defence mechanisms in response to chronic
pulmonary infection [1] or the enhanced reticuloendothelial
clearance of immune complexes seen in patients with CF [4].
We hypothesise that this patient's bacteraemia developed when
P. aeruginosa in swallowed sputum was able to traverse the
inflamed appendiceal wall and enter the bloodstream.
It is known that ingested P. aeruginosa can be recovered
from the faeces [5]. It is also known that in appendicitis, bacteria
can traverse the intact appendiceal wall prior to perforation and
the number of bacteria that do this, increase when there is more
inflammation and tissue damage present [6]. There is a high rate
of portal bacteraemia (45%) seen in patients with confirmed
appendicitis but due to the liver being an effective barrier in
preventing bacteria entering the systemic circulation, only 7%
have systemic bacteraemia [7].
Although P. aeruginosa is the most prevalent pulmonary
pathogen for individuals with CF [8], there are only 3 reported
cases of P. aeruginosa bacteraemia in patients with CF. Two of
these patients were already critically ill with overwhelming
pulmonary infection and respiratory failure (bacteraemia was
confirmed post mortem in one patient and 5 days before death in
the other) [1,2]. The third patient had bacteraemia diagnosed
after presenting with an infective pulmonary exacerbation [9]. Hewas successfully treated with IV and oral anti-pseudomonal
antibiotics. Of note this patient was receiving oral corticosteroids.
Other factors thought to increase the risk of bacteraemia and
fungaemia include other forms of immunosuppression, diabetes
mellitus and the presence of a TIVAD [1].
The P. aeruginosa responsible for this patients bacteraemia
was one of the transmissible strains responsible for the cross-
infection identified at many European, Australian and Canadian
CF centres [3,10–12]. These strains are often multi-resistant and
exhibit a number of unusual phenotypic features [3]. It is not
known if these features have an effect on the mechanisms that
usually prevent systemic bacteraemia in CF patients or if they
affect the response to treatment. Interestingly, despite the
organism being multi-resistant the patient responded well to
intravenous antibiotics.
In summary bacteraemia is rare in patients with CF but it
must be considered in patients who are unwell and febrile,
especially if risk factors, including appendicitis are present.Conflict of interests
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